PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 82 filers reported holding PROTAGONIST THERAPEUTICS INC in Q4 2019. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2023 | $1,848,319 | -19.7% | 80,607 | -3.2% | 0.05% | -6.0% |
| Q2 2023 | $2,300,746 | +15.8% | 83,300 | -3.6% | 0.05% | +25.0% |
| Q1 2023 | $1,987,200 | +333.9% | 86,400 | +49.2% | 0.04% | +233.3% |
| Q2 2022 | $458,000 | -88.8% | 57,923 | -66.5% | 0.01% | -87.4% |
| Q1 2022 | $4,095,000 | +808.0% | 172,941 | +1210.2% | 0.10% | +763.6% |
| Q4 2021 | $451,000 | +176.7% | 13,200 | -42.7% | 0.01% | -21.4% |
| Q1 2020 | $163,000 | +79.1% | 23,039 | +78.7% | 0.01% | +75.0% |
| Q4 2019 | $91,000 | -84.5% | 12,893 | -73.7% | 0.01% | -85.2% |
| Q3 2019 | $588,000 | -54.2% | 48,972 | -53.8% | 0.05% | -53.8% |
| Q2 2019 | $1,283,000 | +857.5% | 105,965 | +432.0% | 0.12% | +485.0% |
| Q4 2018 | $134,000 | – | 19,917 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $84,864,191 | 21.18% |
| Cannon Global Investment Management, LLC | 69,900 | $2,422,035 | 11.28% |
| ADAR1 Capital Management, LLC | 1,603,932 | $55,576,244 | 10.49% |
| Checkpoint Capital L.P. | 355,000 | $12,300,750 | 7.42% |
| Fairmount Funds Management LLC | 931,890 | $32,289,989 | 3.65% |
| BVF INC/IL | 3,319,290 | $115,013,399 | 3.22% |
| RTW INVESTMENTS, LP | 5,286,404 | $183,173,899 | 2.84% |
| Kynam Capital Management, LP | 800,000 | $27,720,000 | 2.14% |
| 683 Capital Management, LLC | 604,449 | $20,944,158 | 1.58% |
| Birchview Capital, LP | 48,000 | $1,663,200 | 1.54% |